Scarica l'app Stockscreener
60.00
3.34%
1.94
Pre-mercato:
58.72
-1.28
-2.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Amova Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position - MarketBeat
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
CRISPR Therapeutics AG $CRSP Position Raised by Vanguard Group Inc. - MarketBeat
Contrarius Group Holdings Ltd Sells 104,604 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Price and Chart — NASDAQ:CRSP - TradingView
Here’s What You Should Understand Besides the Reason CRISPR Therapeutics AG (CRSP) is Gaining Attention - Bitget
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? - The Motley Fool
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
TD Asset Management Inc Sells 53,800 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Rafferty Asset Management LLC Has $10 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - Sahm
HighTower Advisors LLC Reduces Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
FDA Draft Guidance Puts CRISPR Therapeutics Gene Editing Outlook In Focus - Sahm
Crispr Therapeutics AG Surges on Takeover Buzz and Hype - TipRanks
JPMorgan Chase & Co. Buys 294,222 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - Sahm
Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) - Yahoo Finance
CRISPR Therapeutics Hits Day High with 11.85% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth - Intellectia AI
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch - TechStock²
Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.2%Still a Buy? - MarketBeat
Why Is CRISPR Therapeutics Stock Surging Thursday? - Benzinga
Crispr Therapeutics (CRSP) Rumored in M&A Discussions Once More - GuruFocus
Rumor Mill Sends Crispr Therapeutics Shares Climbing Again - TipRanks
Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should You Buy Shares of CRISPR Therapeutics in February? - aol.com
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 57% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Versant Venture Management LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
FDA's New Framework Could Benefit CRISPR Therapeutics (CRSP) - GuruFocus
(CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CRISPR Therapeutics gains after earnings as pipeline hope grows - MSN
Rare disease pharmas could benefit from FDA guidance to accelerate development - Seeking Alpha
Volume Report: Will CRISPR Therapeutics AG benefit from sector rotation2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
O Neil Global Advisors Inc. Acquires Shares of 168,715 CRISPR Therapeutics AG $CRSP - MarketBeat
How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st
Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat
CRISPR Therapeutics (CRSP) CEO sells shares to cover RSU taxes - Stock Titan
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool
First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool
What’s next for CRISPR Therapeutics AG stockJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - sharewise.com
Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case - Yahoo Finance
Breakout Move: Will CRISPR Therapeutics AG benefit from sector rotationJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit - MarketBeat
Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward (NASDAQ:CRSP) - Seeking Alpha
Is CRISPR Therapeutics (CRSP) Turning CASGEVY Momentum Into a Broader Gene-Editing Platform Edge? - Sahm
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) - DirectorsTalk Interviews
Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch (NASDAQ:CRSP) - Seeking Alpha
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):